Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristen D Onos

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Neurobiology of Aging|May 5, 2016
Meox2 haploinsufficiency increases neuronal cell loss in a mouse model of Alzheimer's diseaseIleana Soto, Weronika A Grabowska, Kristen D Onos, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 18, 2020
Improving preclinical to clinical translation in Alzheimer's disease researchStacey J Sukoff Rizzo, Andi Masters, Kristen D Onos, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Genetic context controls early microglia-synaptic interactions in mouse models of Alzheimer's diseaseSarah E Heuer, Kelly J Keezer, Amanda A Hewes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 27, 2023
Control of hippocampal synaptic plasticity by microglia-dendrite interactions depends on genetic context in mouse models of Alzheimer's diseaseSarah E Heuer, Kelly J Keezer, Amanda A Hewes, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Levetiracetam Modulates Brain Metabolic Networks and Transcriptomic Signatures in the 5XFAD Mouse Model of Alzheimer's diseaseCharles P Burton, Evgeny J Chumin, Alyssa Y Collins, et al.
Frontiers in Neuroscience|February 8, 2024
Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's diseaseCharles P Burton, Evgeny J Chumin, Alyssa Y Collins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 8, 2023
STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's diseaseSara K Quinney, Kandasamy Murugesh, Adrian Oblak, et al.
Plos One|May 2, 2015
DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's diseaseHarriet M Jackson, Kristen D Onos, Keating W Pepper, et al.
Journal of Proteome Research|February 3, 2021
Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimer's Disease Mouse ModelsSatoshi Muraoka, Mark P Jedrychowski, Naotoshi Iwahara, et al.
Plos Genetics|June 1, 2019
Enhancing face validity of mouse models of Alzheimer's disease with natural genetic variationKristen D Onos, Asli Uyar, Kelly J Keezer, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Neurobiology of Aging|May 5, 2016
Meox2 haploinsufficiency increases neuronal cell loss in a mouse model of Alzheimer's diseaseIleana Soto, Weronika A Grabowska, Kristen D Onos, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 18, 2020
Improving preclinical to clinical translation in Alzheimer's disease researchStacey J Sukoff Rizzo, Andi Masters, Kristen D Onos, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
Genetic context controls early microglia-synaptic interactions in mouse models of Alzheimer's diseaseSarah E Heuer, Kelly J Keezer, Amanda A Hewes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 27, 2023
Control of hippocampal synaptic plasticity by microglia-dendrite interactions depends on genetic context in mouse models of Alzheimer's diseaseSarah E Heuer, Kelly J Keezer, Amanda A Hewes, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Levetiracetam Modulates Brain Metabolic Networks and Transcriptomic Signatures in the 5XFAD Mouse Model of Alzheimer's diseaseCharles P Burton, Evgeny J Chumin, Alyssa Y Collins, et al.
Frontiers in Neuroscience|February 8, 2024
Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's diseaseCharles P Burton, Evgeny J Chumin, Alyssa Y Collins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 8, 2023
STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's diseaseSara K Quinney, Kandasamy Murugesh, Adrian Oblak, et al.
Plos One|May 2, 2015
DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's diseaseHarriet M Jackson, Kristen D Onos, Keating W Pepper, et al.
Journal of Proteome Research|February 3, 2021
Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimer's Disease Mouse ModelsSatoshi Muraoka, Mark P Jedrychowski, Naotoshi Iwahara, et al.
Plos Genetics|June 1, 2019
Enhancing face validity of mouse models of Alzheimer's disease with natural genetic variationKristen D Onos, Asli Uyar, Kelly J Keezer, et al.
Pageof 3